 | |
| Company type | Public |
|---|---|
| KRX: 207940 | |
| Industry | Biopharmaceuticals |
| Founded | 2011 |
| Headquarters | , South Korea |
Area served | Worldwide |
Key people | John Rim (president and CEO)[1] |
| Revenue |  KRW 3.69 trillion (2023) [2] |
| KRW 1.11 trillion (2023)[2] | |
| Owners |
|
Number of employees | 4,300 (2023) |
| Subsidiaries | Samsung Bioepis |
| Korean name | |
| Hangul | |
| Revised Romanization | Samseong Baiorojikseu |
| McCune–Reischauer | Samsŏng Paiorojiksŭ |
| Website | samsungbiologics |
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer,[3] GlaxoSmithKline,[4] Eli Lilly,[5] AstraZeneca[6] and Bristol-Myers Squibb.[7]
- ^ "Samsung Biologics names John Rim as new chief". The Korea Times. 17 December 2020.
- ^ a b "Samsung Biologics Surpasses 1 Trillion Won in Annual Operating Profit for 1st Time". BusinessKorea. 25 January 2024.
- ^ Cite error: The named reference
Pfizerwas invoked but never defined (see the help page). - ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma. Retrieved 22 July 2024.
- ^ Sagonowsky, Eric (17 November 2020). "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma. Retrieved 22 July 2024.
- ^ Blankenship, Kyle (22 September 2020). "AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push". Fierce Pharma. Retrieved 22 July 2024.
- ^ Lynch, Connor (18 September 2023). "Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody". BioSpace. Retrieved 22 July 2024.